Trial Profile
Phase 1, Open-label, Study of Voruciclib in Subjects With Relapsed and/or Refractory B Cell Malignancies or AML After Failure of Prior Standard Therapies and Voruciclib in Combination With Venetoclax in Subjects With Relapsed/Refractory AML
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 15 Apr 2024
Price :
$35
*
At a glance
- Drugs Venetoclax (Primary) ; Voruciclib (Primary)
- Indications Acute myeloid leukaemia; B-cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma
- Focus Adverse reactions
- Sponsors MEI Pharma
- 11 Apr 2024 According to a MEI Pharma media release, company plans to amend the ongoing Phase 1 study to add a Phase 2 study arm, with enrollment in the Phase 2 arm anticipated to begin in 2025. This is anticipated to generate Phase 2 data by the end of 2025.
- 26 Mar 2024 Results presented in a MEI Pharma Media Release.
- 26 Mar 2024 According to a MEI Pharma media release, a total of 29 patients with R/R AML, median age 67 years (range 34-89), were enrolled in the dose escalation stage of the study .